PARP Inhibitors in Prostate Cancer: A Promise Delivered

被引：2
|
作者：
Tripathi, Abhishek [1 ]
McFarland, Taylor [2 ]
Agarwal, Neeraj [2 ]
机构：
[1] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA
[2] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
来源：
EUROPEAN UROLOGY ONCOLOGY | 2020年 / 3卷 / 05期
关键词：
MUTATIONS;
D O I：
10.1016/j.euo.2020.08.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：612 / 614
页数：3
相关论文
共 50 条
  • [41] Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer
    Su, Christopher T.
    Nizialek, Emily
    Berchuck, Jacob E.
    Vlachostergios, Panagiotis J.
    Ashkar, Ryan
    Sokolova, Alexandra
    Barata, Pedro C.
    Aggarwal, Rahul R.
    McKay, Rana R.
    Agarwal, Neeraj
    McClure, Heather M.
    Nafissi, Nellie
    Bryce, Alan H.
    Sartor, Oliver
    Sayegh, Nicolas
    Cheng, Heather H.
    Adra, Nabil
    Sternberg, Cora N.
    Taplin, Mary-Ellen
    Cieslik, Marcin
    Alva, Ajjai S.
    Antonarakis, Emmanuel S.
    PROSTATE, 2023, 83 (03) : 227 - 236
  • [42] PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations
    Vanacker, Helene
    Harter, Philipp
    Labidi-Galy, Sana Intidhar
    Banerjee, Susana
    Oaknin, Ana
    Lorusso, Domenica
    Ray-Coquard, Isabelle
    CANCER TREATMENT REVIEWS, 2021, 99
  • [43] Exceptional responses to PARP inhibitors in patients with metastatic breast cancer in oncologic crisis
    Cheng, Joyce M.
    Canzoniero, Jenna
    Lee, Seoho
    Soni, Sudeep
    Mangini, Neha
    Santa-Maria, Cesar A.
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 199 (02) : 389 - 397
  • [44] PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine
    Mukhopadhyay, A.
    Curtin, N.
    Plummer, R.
    Edmondson, R. J.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2011, 118 (04) : 429 - 432
  • [45] PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research
    Gadducci, Angiolo
    Guerrieri, Maria Elena
    ANTICANCER RESEARCH, 2016, 36 (05) : 2055 - 2064
  • [46] Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
    Duma, Narjust
    Gast, Kelly C.
    Choong, Grace M.
    Leon-Ferre, Roberto A.
    O'Sullivan, Ciara C.
    CURRENT ONCOLOGY REPORTS, 2018, 20 (08)
  • [47] Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus
    Redondo, Andres
    Barretina, Pilar
    Perez-Fidalgo, Alejandro
    Rubio, Maria Jesus
    Gonzalez-Martin, Antonio
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2023, 34 (05)
  • [48] Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
    Wiggans, Alison J.
    Cass, Gemma K. S.
    Bryant, Andrew
    Lawrie, Theresa A.
    Morrison, Jo
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (05):
  • [49] BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer
    Lui, Goldie Y. L.
    Shaw, Reid
    Schaub, Franz X.
    Stork, Isabella N.
    Gurley, Kay E.
    Bridgwater, Caroline
    Diaz, Robert L.
    Rosati, Rachele
    Swan, Hallie A.
    Ince, Tan A.
    Harding, Thomas C.
    Gadi, Vijayakrishna K.
    Goff, Barbara A.
    Kemp, Christopher J.
    Swisher, Elizabeth M.
    Grandori, Carla
    EBIOMEDICINE, 2020, 60
  • [50] PARP Inhibitors Resistance: Mechanisms and Perspectives
    Giudice, Elena
    Gentile, Marica
    Salutari, Vanda
    Ricci, Caterina
    Musacchio, Lucia
    Carbone, Maria Vittoria
    Ghizzoni, Viola
    Camarda, Floriana
    Tronconi, Francesca
    Nero, Camilla
    Ciccarone, Francesca
    Scambia, Giovanni
    Lorusso, Domenica
    CANCERS, 2022, 14 (06)
12345